UCSF Faculty Appointed to Advisory Board
Press release reprinted from Reuters.
ALACHUA, FL--(Marketwired - March 17, 2015) - CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that develop cyclodextrin-based treatments, including the orphan drug designated Trappsol® Cyclo™, today announced the appointment of Caroline Hastings, M.D., to the company's Scientific Advisory Board. Dr. Hastings joins Dr. Sharon Hrynkow, President of Global Virus Network and Founder and Managing Partner of Global Health Consulting LLC, in advising the Company.
Dr. Hastings has been on the faculty of UCSF Benioff Children's Hospital Oakland since 1992. She is Board Certified in Pediatric Hematology-Oncology. Dr. Hastings is a dedicated clinician and has been a leader in establishing a hematology specialty outreach clinic and practice in Northern Nevada. Additionally, Dr. Hastings is the Director of the fellowship training program in Pediatric Hematology-Oncology at UCSF Benioff Children's Hospital Oakland and is on the board of trustees for the American Society of Pediatric Hematology-Oncology in which she serves as an advocate for childhood cancer research and education.
In 2008, Dr. Hastings worked with the Hempel family to pioneer the treatment of Niemann-Pick Type C using cyclodextrin-based I.V. infusions to remove excess cholesterol from the patients. CTD provided the first generation of its Trappsol® Cyclo™ orphan drug product to Dr. Hastings and the Hempel family, and assisted them in filing the first Investigational New Drug protocol with the U.S. FDA, authorizing compassionate use of the product for the Hempel's children. In 2010 Dr. Hastings was granted Orphan Drug status for Trappsol® Cyclo™ to use in the treatment of Niemann-Pick Type C, a rare and tragic disease.
"I am especially gratified that Dr. Hastings is joining our Scientific Advisory Board," said Dr. Jeffrey Tate, President and CEO of CTD. "She has been a tireless pioneer in the treatment of children with Niemann-Pick Type C, and her immense experience and clinical expertise will be invaluable to our group of advisors."
"It is an honor to be invited to join this prestigious organization and participate in the development of this drug for patients with Niemann-Pick Type C," said Dr. Hastings. "The first kids who received this drug, and their parents, have entrusted themselves to us to develop this drug so that future patients may benefit with an improved quality of life. Now, we are in a position to move forward."
Now that the smoke has cleared, are we in the clear?Details
In utero transplants may become the new norm.Details